A high-dose version of Novo Nordisk's injectable obesity drug Wegovy received U.S. FDA approval on March 19, 20261
The therapy was approved under a new voucher program established by FDA Commissioner Marty Makary to accelerate review of drugs aligned with national priorities1
Novo Nordisk received the voucher as part of its deal with the Trump administration to lower prices of its obesity medicines in certain settings1
The high-dose Wegovy approval provides a new catalyst for Novo Nordisk as it attempts to regain market share in the obesity drug market, where it has fallen behind competitor Eli Lilly in recent years1
Novo Nordisk previously achieved FDA approval for an oral 25 mg Wegovy pill on December 22, 2025, the first FDA-approved oral GLP-1 therapy for chronic weight management, with a planned U.S. launch in early January 20262
Sources:
1. https://www.statnews.com/2026/03/19/wegovy-novo-norisk-high-dose-approved/
2. https://www.biospace.com/press-releases/best-semaglutide-options-for-2026-new-oral-wegovy-pill-approved-by-fda-as-patients-compare-injectable-and-compounded-access-pathways